The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications
Authors' conclusion
COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes.
Study context
- Population
- Individuals eligible for vaccination with no previous SARS-CoV-2 infection or COVID-19 vaccine, UK, Spain and Estonia
- Exposure
- COVID-19 vaccination vs no vaccination
- Vaccinatedn = 10.17 million
- Unvaccinatedn = 10.39 millionreference
- Outcome
- Heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) after SARS-CoV-2 infection
- Follow-up
- 0-30, 31-90, 91-180 and 181-365 days
Methodological detailsmultinational electronic health records (UK, Spain, Estonia), propensity score overlap weighting, empirical calibration, random effect meta-analysis across cohorts and databases
- Multinational electronic health records (UK, Spain, Estonia)
- Propensity score overlap weighting
- Empirical calibration
- Random effect meta-analysis across cohorts and databases
Main finding
As reported in the abstract
Post-COVID-19 VTE, ATE and HF · 0-30 days after SARS-CoV-2 infection
Vaccinated vs UnvaccinatedSubdistribution hazard ratio (95% CI)
VTE
0.22(0.17–0.29)
ATE
0.53(0.44–0.63)
HF
0.45(0.38–0.53)
Observational data: associations, not effects.
Further findings
| Outcome | sHR (95% CI) | |
|---|---|---|
| Post-COVID-19 VTE, ATE and HF · 91-180 daysVaccinated vs Unvaccinated · VTE | 0.53 (0.40–0.70) | |
| Post-COVID-19 VTE, ATE and HF · 91-180 daysVaccinated vs Unvaccinated · ATE | 0.72 (0.58–0.88) | |
| Post-COVID-19 VTE, ATE and HF · 91-180 daysVaccinated vs Unvaccinated · HF | 0.61 (0.51–0.73) | |
| 0.512Subdistribution hazard ratio (log scale) |
Original publication
The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. Heart. Published 12 March 2024. doi:10.
Summarised from the published abstract; every number is checked against it